Literature DB >> 2737230

Kinetics of oral and intravenous mexiletine: lack of effect of cimetidine and ranitidine.

N H Brockmeyer1, H Breithaupt, W Ferdinand, M von Hattingberg, E E Ohnhaus.   

Abstract

The pharmacokinetics of mexiletine, a Class I antiarrhythmic drug, was investigated in 6 healthy volunteers after single oral doses and 15 min intravenous infusions of 3 mg/kg. Cimetidine and ranitidine are commonly used H2-receptor antagonists, which interact adversely with many drugs, e.g. inhibition of the metabolism of Class I antiarrhythmics such as lidocaine and quinidine by cimetidine. To investigate the effects of the two drugs on the kinetics of mexiletine, cimetidine 800 mg.day-1 or ranitidine 600 mg.day-1 were administered orally for one week. Neither H2-receptor antagonist altered the distribution and elimination of mexiletine, nor did they affect its overall kinetics, or excretion of the metabolites para- and 4-OH-methylmexiletine after oral and intravenous administration of mexiletine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737230     DOI: 10.1007/bf00558298

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  The distribution, metabolism and excretion of mexiletine in man.

Authors:  A H Beckett; E C Chidomere
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Interaction of cimetidine with tetracycline absorption.

Authors:  H J Rogers; F R House; P J Morrison; I D Bradbook
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

3.  The influence of gastric acidity on the bio-availability of ketoconazole.

Authors:  J W Van Der Meer; J J Keuning; H W Scheijgrond; J Heykants; J Van Cutsem; J Brugmans
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

4.  Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction.

Authors:  R W Campbell; S C Achuff; A Pottage; A Murray; L F Prescott; D G Julian
Journal:  J Cardiovasc Pharmacol       Date:  1979 Jan-Feb       Impact factor: 3.105

5.  The clinical pharmacology of mexiletine.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

6.  Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.

Authors:  B G Mitchell; J A Clements; A Pottage; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

7.  Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration.

Authors:  W M Steinberg; C E King; P P Toskes
Journal:  Dig Dis Sci       Date:  1980-03       Impact factor: 3.199

8.  Determination of mexiletine in biological fluids by high-performance liquid chromatography.

Authors:  H Breithaupt; M Wilfling
Journal:  J Chromatogr       Date:  1982-06-11

9.  Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease.

Authors:  J Nitsch; G Steinbeck; B Lüderitz
Journal:  Eur Heart J       Date:  1983-11       Impact factor: 29.983

10.  Kinetics and bioavailability of mexiletine in healthy subjects.

Authors:  V Häselbarth; J E Doevendans; M Wolf
Journal:  Clin Pharmacol Ther       Date:  1981-06       Impact factor: 6.875

View more
  4 in total

Review 1.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 2.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 3.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 4.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.